Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Astellas Pharma
Thumbnail
April 21, 2022

Jumping aboard the Claudin18.2 bandwagon

Thumbnail
April 11, 2022

AACR 2022 – A weekend of updates yields few winners

The dour biotech market sees little to be impressed about in updates from Bicycle, Rubius, C4 and Zentalis, though well-received data gives Affimed a boost.

Article image
Vantage logo
February 28, 2022

A big year for sickle cell

Novel approaches including gene editing are creeping towards approval.

Article image
Vantage logo
February 10, 2022

Seagen delivers a triple blow

Article image
Vantage logo
November 19, 2021

Daiichi could be rewarded for persisting with Vanflyta

A front-line trial yields a positive result two years after the drug got a US complete response letter.

Article image
Vantage logo
November 08, 2021

ASN 2021 – Glaxo’s daprodustat delivers

But whether data on the novel anaemia pill are clean enough to dispel wider FDA toxicity concerns is hard to call.

Article image
Vantage logo
October 11, 2021

Triple meeting – low-profile assets boost Merus and Bicycle

Merus regains some lost pride while Bicycle rides to even greater heights.

Article image
Vantage logo
September 14, 2021

Astellas readies roxadustat for launch

But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.

Article image
Vantage logo
September 14, 2021

The picture worsens for Astellas’s gene therapy

Article image
Vantage logo
September 07, 2021

Roche U-turns and Adaptimmune wins

A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.

Article image
Vantage logo
September 06, 2021

Novartis pushes on with iscalimab after transplant disappointment

The autoimmune target CD40 has yielded few hits despite years of research, but a few companies are keeping the faith.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.